How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Business Services · Forecast 2027–2033
Extraction of traditional Chinese Medicine Market
- By Extraction Method: Solvent Extraction, Ultrasonic Extraction, Supercritical Fluid Extraction, Steam Distillation, Enzyme-Assisted Extraction
- By Source Material: Roots and Rhizomes, Leaves and Stems, Flowers and Blossoms, Fruits and Seeds, Bark and Wood
- By End-Use Application: Pharmaceuticals, Nutraceuticals, Cosmetics, Food and Beverage, Health Supplements
- By Product Form: Liquid Extracts, Powdered Extracts, Concentrates, Essential Oils, Tinctures
- By Extraction Scale: Laboratory Scale, Pilot Scale, Industrial Scale
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Solvent Extraction leads By Extraction Method at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 300 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.183 →
- 12 Company Profiles 15 players: SWOT & benchmarking p.191 →
Full report · locked preview
Everything inside the Extraction of traditional Chinese Medicine Market report
A complete, evidence-based study - 12 chapters and 126 sections covering market size, segmentation across 5 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Extraction Method 5
Source Material 5
End-Use Application 5
Product Form 5
Extraction Scale 3
Companies profiled
Tasly Pharmaceutical Group Co. Ltd.
Tongrentang (Beijing Tong Ren Tang Co. Ltd.)
China Traditional Chinese Medicine Holdings Co. Ltd.
Yunnan Baiyao Group Co. Ltd.
Guangzhou Baiyunshan Pharmaceutical Holdings Co. Ltd.
Jiangyin Tianjiang Pharmaceutical Co. Ltd.
Shandong Buchang Pharmaceuticals Co. Ltd.
Hunan Jiudian Group Co. Ltd.
Harbin Pharmaceutical Group Co. Ltd. (Hayao)
Inner Mongolia First Machinery Group Co. Ltd.
Shaanxi Sciphar Natural Products Co. Ltd.
Guizhou Yibai Pharmaceutical Co. Ltd.
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Tasly Pharmaceutical Group Co. Ltd.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Tongrentang (Beijing Tong Ren Tang Co. Ltd.)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →China Traditional Chinese Medicine Holdings Co. Ltd.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Yunnan Baiyao Group Co. Ltd.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Guangzhou Baiyunshan Pharmaceutical Holdings Co. Ltd.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Jiangyin Tianjiang Pharmaceutical Co. Ltd.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Shandong Buchang Pharmaceuticals Co. Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Hunan Jiudian Group Co. Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Harbin Pharmaceutical Group Co. Ltd. (Hayao)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Inner Mongolia First Machinery Group Co. Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Shaanxi Sciphar Natural Products Co. Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Guizhou Yibai Pharmaceutical Co. Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Jiangsu Kanion Pharmaceutical Co. Ltd.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Zhejiang Conba Pharmaceutical Co. Ltd.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Guangdong Yifang Pharmaceutical Co. Ltd.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$11,365M by 2033 · 11.2% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Solvent Extraction33.9
- Ultrasonic Extraction15.3
- Supercritical Fluid Extraction16.9
- Steam Distillation16.2
- Enzyme-Assisted Extraction17.7
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,606M → $3,768M · 11.2%
Europe$1,119M → $2,436M · 10.2%
Asia Pacific$1,022M → $2,544M · 12.1%
Latin America$632.6M → $1,630M · 12.6%
Middle East and Africa$486.6M → $1,032M · 9.8%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →11.152026
11.152027
11.172028
11.172029
11.202030
11.192031
11.212032
11.222033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Tasly Pharmaceutical Group Co. Ltd.17.1
- Tongrentang (Beijing Tong Ren Tang Co. Ltd.)19.0
- China Traditional Chinese Medicine Holdings Co. Ltd.8.9
- Yunnan Baiyao Group Co. Ltd.10.8
- Guangzhou Baiyunshan Pharmaceutical Holdings Co. Ltd.10.7
- Jiangyin Tianjiang Pharmaceutical Co. Ltd.5.4
- Others28.1
Segment contribution to growth (%)
Fig. 18 · p.39 →Extraction Method19.7%
Source Material20.1%
End-Use Application21.2%
Product Form21.7%
Extraction Scale17.4%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America33.0
- Europe21.4
- Asia Pacific22.3
- Latin America14.3
- Middle East and Africa9.0
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Tasly Pharmaceutical Group Co. Ltd. | 78 | 90 | 97 | 95 | 83 | 95 | 90 |
| Tongrentang (Beijing Tong Ren Tang Co. Ltd.) | 80 | 88 | 74 | 72 | 70 | 84 | 78 |
| China Traditional Chinese Medicine Holdings Co. Ltd. | 88 | 78 | 64 | 67 | 74 | 87 | 76 |
| Yunnan Baiyao Group Co. Ltd. | 63 | 67 | 70 | 79 | 59 | 79 | 70 |
| Guangzhou Baiyunshan Pharmaceutical Holdings Co. Ltd. | 69 | 72 | 76 | 70 | 54 | 74 | 69 |
| Jiangyin Tianjiang Pharmaceutical Co. Ltd. | 61 | 67 | 48 | 70 | 63 | 49 | 60 |
| Shandong Buchang Pharmaceuticals Co. Ltd. | 48 | 52 | 54 | 50 | 61 | 65 | 55 |
| Hunan Jiudian Group Co. Ltd. | 55 | 40 | 54 | 57 | 57 | 45 | 51 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Tasly Pharmaceutical Group Co. Ltd.
- Tongrentang (Beijing Tong Ren Tang Co. Ltd.)
- China Traditional Chinese Medicine Holdings Co. Ltd.
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Tasly Pharmaceutical Group Co. Ltd. | ◐ | ◐ | ✓ | ✓ | ✓ | ✓ |
| Tongrentang (Beijing Tong Ren Tang Co. Ltd.) | ◐ | ◐ | ◐ | ◐ | ◐ | ✓ |
| China Traditional Chinese Medicine Holdings Co. Ltd. | ◐ | ✓ | − | − | ◐ | ◐ |
| Yunnan Baiyao Group Co. Ltd. | ◐ | ◐ | ◐ | ✓ | ◐ | ✓ |
| Guangzhou Baiyunshan Pharmaceutical Holdings Co. Ltd. | − | ✓ | ✓ | − | ◐ | ◐ |
| Jiangyin Tianjiang Pharmaceutical Co. Ltd. | − | ◐ | ◐ | − | − | ◐ |
| Shandong Buchang Pharmaceuticals Co. Ltd. | ◐ | − | ◐ | − | ◐ | − |
| Hunan Jiudian Group Co. Ltd. | − | − | − | ◐ | ◐ | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Tasly Pharmaceutical Group Co. Ltd.90
2Tongrentang (Beijing Tong Ren Tang Co. Ltd.)78
3China Traditional Chinese Medicine Holdings Co. Ltd.76
4Yunnan Baiyao Group Co. Ltd.70
5Guangzhou Baiyunshan Pharmaceutical Holdings Co. Ltd.69
6Jiangyin Tianjiang Pharmaceutical Co. Ltd.60
7Shandong Buchang Pharmaceuticals Co. Ltd.55
8Hunan Jiudian Group Co. Ltd.51
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Tasly Pharmaceutical Group Co. Ltd.Tongrentang (Beijing Tong Ren Tang Co. Ltd.)
Challenger3
Strong scale, closing on the leaders.
China Traditional Chinese Medicine Holdings Co. Ltd.Yunnan Baiyao Group Co. Ltd.Guangzhou Baiyunshan Pharmaceutical Holdings Co. Ltd.
Contender1
Focused players with pockets of strength.
Jiangyin Tianjiang Pharmaceutical Co. Ltd.
Niche2
Specialists in a single segment or region.
Shandong Buchang Pharmaceuticals Co. Ltd.Hunan Jiudian Group Co. Ltd.
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Extraction Method in North America, then scale across Extraction of traditional Chinese Medicine Market — a $356M beachhead inside a $5.70B market.
Beachhead (SOM)$356Mobtainable near-term
Serviceable (SAM)$1.98Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale6 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion88 fit
Solvent Extraction
Best fit — highest urgency & budget in Extraction Method.
Economic buyer79 fit
Ultrasonic Extraction
Strong fit — clear ROI and a fast path to value.
End user67 fit
Supercritical Fluid Extraction
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Extraction Method in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Source Material & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + End-Use Application
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales48%
Partner / channel27%
Digital / self-serve17%
Marketplaces8%
Positioning & messaging
§GTM 2 · p.194 →For Extraction Method leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Extraction of traditional Chinese Medicine Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified44%
Sales qualified24%
Evaluation11%
Closed-won6%
$11.9KCAC
$61KLTV
5.2:1LTV : CAC
< 4 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Extraction of traditional Chinese Medicine Market is a durable-growth opportunity — $3.79B by 2033, compounding at 8.3%.
TAM · 2025$2.01Btoday
TAM · 2033$3.79Bforecast
CAGR8.3%2027–2033
Cumulative$25.3Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$3.79BTotal addressable market
SAM$1.30BServiceable available market
SOM$263MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →8.3% CAGR
Demand compounds through 2033, outpacing GDP across Extraction Method.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Extraction Method moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$3.79BLarge & growingTAM by 2033 at 8.3% CAGR
$1.30BServiceable nowreachable with today’s model
$263MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$2.95BBear5.4% CAGR
$3.79BBase8.3% CAGR
$4.85BBull10.9% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Source Material optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Extraction of traditional Chinese Medicine Market — a $2.03B market by 2033. Plan: grow share from 7.6% to 16.8%.
Market size · 2033$2.03Btotal addressable
Market CAGR5.8%2027–2033
Target share16.8%from 7.6% today
Revenue ambition$341Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 7.6% | 16.8% | On track |
| Revenue | $156M | $341M | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Behind |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | On track |
| Gross margin | 30.7% | 45.2% | On track |
| Customer retention | 89.7% | 95.4% | At risk |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Extraction Method
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Source Material capability
A defensible second engine — invest in Source Material to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Extraction Method share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Source Material
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $49M capacity & capability investment
- Greenlight bolt-on M&A in Source Material
- Authorise North America expansion plan
- Fund R&D program for Extraction Method leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAhead
- Competitive share lossAhead
- Input-cost & supply riskAt risk
- Regulatory / policy changeOn track
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Extraction of traditional Chinese Medicine Market conversation — a $2.66B market you can size, segment and defend in minutes.
Market size · 2033$2.66Btotal opportunity
Growth9.0%CAGR to 2033
Addressable buyers1,796+accounts in scope
Typical ROI5.9×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Extraction Method
Goal Grow share in Extraction Method
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →5.9×return on cost, year one
< 2 mopayback period
$66K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
Tasly Pharmaceutical Group Co. Ltd.Tongrentang (Beijing Tong Ren Tang Co. Ltd.)China Traditional Chinese Medicine Holdings Co. Ltd.Yunnan Baiyao Group Co. Ltd.Guangzhou Baiyunshan Pharmaceutical Holdings Co. Ltd.Jiangyin Tianjiang Pharmaceutical Co. Ltd.Shandong Buchang Pharmaceuticals Co. Ltd.Hunan Jiudian Group Co. Ltd.+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Extraction of traditional Chinese Medicine Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Extraction of traditional Chinese Medicine Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Business Services · scroll →Extraction Parachute Market
Market size, share, segmentation and regional forecast.
$6.1B market · 2025 base year
View reportExtraction Resin Market
Market size, share, segmentation and regional forecast.
$4.3B market · 2025 base year
View reportExtraction System Market
Market size, share, segmentation and regional forecast.
$5.8B market · 2025 base year
View reportExtractor Fans Market
Market size, share, segmentation and regional forecast.
$4.4B market · 2025 base year
View reportExtractors Market
Market size, share, segmentation and regional forecast.
$4.4B market · 2025 base year
View reportExtra-high Voltage Cable Market
Market size, share, segmentation and regional forecast.
$1.3B market · 2025 base year
View reportExtraoral Suction System Market
Market size, share, segmentation and regional forecast.
$5.5B market · 2025 base year
View reportExtraoral X-Ray Systems Market
Market size, share, segmentation and regional forecast.
$536M market · 2025 base year
View reportExtrapyramidal Reaction Market
Market size, share, segmentation and regional forecast.
$5.2B market · 2025 base year
View reportExtreme High Capacity Recirculating Chillers Market
Market size, share, segmentation and regional forecast.
$3.9B market · 2025 base year
View reportExtreme High Temperature Grease Market
Market size, share, segmentation and regional forecast.
$713M market · 2025 base year
View reportExtreme Ultraviolet (Euv) Lithography Equipment Market
Market size, share, segmentation and regional forecast.
$716M market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.